Good morning,
A new vaccine for those six and under is on the horizon, and it could eliminate the final barrier keeping employers from asking most employees to come back to the office.
This week, biotech company Moderna announced that its second phase of vaccine studies for children under six has successfully met “primary endpoints,” meaning that young children who received the vaccine in the study had a similar immune response against the virus as seen in adults. Based on the study, Moderna plans to submit a request for authorization of a two-dose primary series of the vaccine for children under six years of age to the U.S. Food and Drug Administration (FDA).
As many companies started to call employees back to the office, some parents declined, fearing they might bring the infection home to their youngest children. Read on for what Moderna’s latest move may mean for employers aiming to fill up their desks again with more employees–and new talent.
Inc. 5000. Call For Entries
Apply now to be recognized as one of America's fastest-growing private companies!
|
0 Comments:
Post a Comment